Clinical Trial Finder

Inclusion Criteria:

1. After brain surgery (patients with total resection, partial resection and biopsy were acceptable), the pathological examination confirmed glioblastoma with IDH wild-type according to the 2021 WHO classification of tumors of the central nervous system. 2. The age of the subjects was ≥18 years old; 3. Supratentorial tumors; 4. Patients who had undergone maximal surgical resection (biopsy) and completed TMZ concurrent chemoradiotherapy were planned for adjuvant TMZ treatment. 5. KPS score ≥70; 6. The predicted survival time was ≥3 months. 7. Voluntarily signed informed consent; 8. Subjects of childbearing potential had to agree to use effective contraception for the duration of the trial.

Exclusion Criteria:

1. Early progression of GBM occurred after TMZ+RT treatment (except pseudoprogression, imaging examination should be supplemented to further exclude if necessary). 2. The subject had received any other cytotoxic or biologic antineoplastic therapy before enrollment; 3. Distant leptomeningeal metastasis; 4. Patients had a diagnosis of cancer other than glioblastoma and received antineoplastic therapy within 5 years before enrollment, excluding cured stage I prostate cancer, cervical or uterine cancer in situ, breast cancer in situ, and nonmelanoma skin cancer. 5. Previous treatment with anti-PD-1 antibody/anti-PD-L1 antibody and anti-CTLA-4 antibody; 6. Participants who had received systemic immunosuppressive therapy (including but not limited to glucocorticoids, cyclophosphamide, azathioprine, methotrexate, thalidomide, or antineoplastic factor agents) within 2 weeks before enrollment. Excluding nasal sprays and inhaled corticosteroids; 7. The presence of an active, known, or suspected autoimmune disease that was judged by the investigator to be unsuitable for this study. The following exclusions may be made: vitiligo, alopecia, Graves' disease, psoriasis, or eczema that did not require systemic treatment within the previous 2 years; Hypothyroidism (due to autoimmune thyroiditis) that is asymptomatic or requires only stable doses of hormone-replacement therapy or type I diabetes that requires only stable doses of insulin-replacement therapy, or childhood asthma that has resolved completely without intervention or recurrence in adulthood without an external trigger. 8. Participants had to meet certain criteria for bone marrow, liver and kidney function before enrollment, and were not eligible if they had any of the following: 1. Thrombocytopenia (platelet count < 100×103/μL) 2. Neutropenia (absolute neutrophil count < 1.5×103/μL) 3. NCCI-CTCAE4 grade non-hematologic toxicity (except alopecia, nausea and vomiting) 4. Significant liver function impairment -AST or ALT exceeding 3 times the upper limit of normal. 5. Total bilirubin more than 1.5 times the upper limit of the normal range. 6. Severe renal impairment (serum creatinine >1.7 mg/dL, or >150 μmol/L). 9. The subject had an active implanted device (deep brain stimulator, spinal cord stimulator, vagus nerve stimulator, pacemaker, cardiac defibrillator, etc.). 10. Infratentorial tumors; 11. Documented increased intracranial pressure (clinically manifested as severe papilledema, vomiting, nausea, or decreased consciousness); 12. There were infection, ulcer and unhealed wound in the skin where the electrode was applied. 13. A known history of allergy to TMZ or tislelizumab; 14. Skull defects or residual metal fragments in the skull (except titanium plates or nails used for skull surgery); 15. Patients allergic to conductive hydrogels or medical adhesives; 16. Those who are pregnant or preparing to become pregnant or who are breastfeeding; 17. Patients with poor compliance, as judged by the investigator, or other factors considered by the investigator to be not suitable for the study.

Arms

Experimental: Tumor Treating Fields + Temozolomide + Tislelizumab

Interventions

Device: - Tumor Treating Fields

Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day, starting on the C1D1, throughout the entire course of treatment.

Drug: - Tislelizumab

Tislelizumab will be given 300 mg intravenously every 4 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. The Tislelizumab treatment should be continued until confirmed PD, unacceptable toxicity, or finished Tislelizumab treatment for other reasons.

Drug: - Temozolomide (TMZ)

The patients will carry out 6 cycles of TMZ adjuvant chemotherapy according to the instructions. The dosage of TMZ is 150-200 mg/(m2·d), daily for 5 days followed by 23 days without treatment, the treatment cycle is 28 days. The initial dose of cycle 1 is 150 mg/(m2·d), if patients do not experience TMZ chemotherapy toxicity, the dose should be increased to 200 mg/(m2·d) in subsequent treatment cycles. After 6 cycles of TMZ adjuvant chemotherapy, if the patients do not experience disease progression, it is recommended to continue TMZ adjuvant chemotherapy, or treated according to investigators' recommendations. The TMZ treatment should be continued until confirmed PD, unacceptable toxicity, or finished TMZ treatment for other reasons.